Novartis steps up coronavirus fight as part of new collaboration
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation to scale up solutions and support health systems in response to the coronavirus pandemic.
This content was published on
2 minutes
Keystone-SDA/jdp
العربية
ar
نوفارتيس تنشط كطرف في تحالف جديد لمكافحة الفيروس المستجد
On Thursday, Basel-based pharmaceutical giant Novartis announced that CEO Vas Narasimhan would be the co-chair of a consortium of life science companies to speed up the development and delivery of vaccines, diagnostics and treatments for Covid-19 as well as other solutions.
“We feel a deep shared responsibility to see if there are specific areas where collaboration across the life sciences industry and the Bill & Melinda Gates Foundation can accelerate solutions to this pandemic,” said Narasimhan in a statementExternal link.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
The consortium is intended to help ramp up solutions and tap the industry’s scientific knowledge and experience in delivering products at a scale of billions per day.
As a first step, the 15 companies that are part of the consortium have agreed to share their proprietary libraries of molecular compounds with the Covid-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard two weeks ago. The accelerator will screen them for potential use against Covid-19 and if there are successful hits, the compounds would move rapidly into in vivo trials in as little as two months.
Other companies that have teamed up in the consortium include GSK, Pfizer and Gilead. Gilead’s drug Remdesivir is an intravenous, antiviral medicine that is being studied in clinical trials as a treatment to Covid-19.
Last week, Novartis announced it was donating up to 130 million doses of generic hydroxychloroquine, which along with a related drug, chloroquine, is currently under evaluation in clinical trials for the treatment of Covid-19.
The company has also created a Covid-19 Response FundExternal link providing $20 million (CHF 19 million) in grants to support public health initiatives for communities affected by the pandemic.
Novartis is one of several big pharmaceutical companies that has moved out of the emerging infectious disease business. In 2014, the Swiss company sold its vaccine business to British pharma company GSK after operating at a loss for years. The company no longer has critical mass of expertise in virology, and no laboratories are working on antivirals or diagnostics.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
More
More
With no prospects for profits, big pharma neglects new infectious diseases
This content was published on
More companies are shifting resources away from emerging infectious diseases into more lucrative areas like cancer. What does this mean for Covid-19?
How is your country dealing with the return of stolen artifacts?
Western nations like Switzerland often have to deal with the process of recovering or returning looted artifacts which have been illegally imported. What’s the situation like in your country?
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
Algerian to face trial in in Switzerland for ties to Islamic State
This content was published on
A 51-year-old Algerian man has been charged by the Swiss Federal Prosecutor's Office for involvement in the banned terrorist group.
Sylvain Saudan, ‘skier of the impossible’, dies aged 87
This content was published on
The Swiss father of extreme skiing pioneered descents from the Alps to the Himalayas – and became the sport’s first star.
Hayek family buys additional Swatch shares for nearly CHF11 million
This content was published on
Following the acquisition of registered shares worth over CHF20.6 million on Monday, the Hayek family made another purchase on Tuesday.
Suicide capsule to be used in Switzerland this year, says euthanasia organisation
This content was published on
The organisation “The Last Resort” has confirmed that the suicide capsule Sarco is to be used in Switzerland. This should happen this year, it said.
Ukrainian children flown to Switzerland for cancer treatment
This content was published on
The Swiss air rescue service Rega flew two Ukrainian children with cancer to Switzerland from a hospital in Kyiv hit by Russian missiles.
Swiss Solidarity raises over CHF10 million for victims of extreme weather
This content was published on
The money raised will be used to help those affected by the recent storms and flooding in the cantons of Ticino, Graubünden, and Valais.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
Swiss restrict exports of protective equipment as coronavirus hits
This content was published on
Switzerland has introduced temporary restrictions on the export of protective equipment to head off shortages among medical staff and others.
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.